financetom
Business
financetom
/
Business
/
LSEG first-half income rises 5.4%, progress on Microsoft JV
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LSEG first-half income rises 5.4%, progress on Microsoft JV
Aug 1, 2024 12:24 AM

LONDON, Aug 1 (Reuters) - London Stock Exchange Group ( LDNXF )

reported first half income above analysts' consensus on

Thursday, and a rise in annual subscription value, saying it was

sticking with its medium-term earnings growth guidance.

LSEG's total income excluding recoveries in the first half

of 2024 was 4.204 billion pounds ($5.40 billion), up 5.4% on the

the first half of 2023, and above analysts' consensus of 4.195

billion pounds.

Operating profit in the first half rose 9% to 1.563 billion

pounds, with adjusted earnings per share of 174 pence, up 8.1%

on the same period last year, both ahead of analysts' consensus

estimates collated by LSEG.

Annual subscription value (ASV), which reflects recurring

revenue and closely watched by analysts, was up 6.4% at June

2024, in line with guidance, and up from 6% in the first

quarter.

"We are also delivering efficiency improvements, with

underlying margin improving year-on-year despite ongoing

investment, and we expect this trend to continue," LSEG CEO

David Schwimmer, said in a statement.

"We look forward to further progress in the second half of

the year, and are reiterating all of our medium-term guidance."

LSEG said its partnership with Microsoft ( MSFT ) is "approaching

commercialisation" as the first product becomes more widely

available by year-end.

The exchange, transformed into a data powerhouse after

its $27 billion acquisition of Refinitiv in 2021, reiterated all

medium-term guidance of mid to high single digit organic revenue

growth annually, accelerating after this year.

LSEG said its recently announced content agreement with

Dow Jones creates a leading news offering across its platforms.

LSEG pays Reuters for news.

($1 = 0.7785 pounds)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved